MAI-KNEE™
Precision motion analysis with anatomical integration.
MAI-KNEE™ is a strategic innovation programme developed by MSK Doctors & Associates, designed to transform the diagnosis and stratification of knee osteoarthritis through the integration of dynamic movement data and anatomical imaging.
This initiative was formally submitted to the Innovate UK Smart Grants programme (July 2024 competition) and continues to evolve within our active innovation pipeline.
The Clinical Challenge
The knee is the most commonly affected joint — and the hardest to read.
528m+
People living with osteoarthritis globally
5m+
Individuals impacted in the UK alone
Rising
Prevalence increasing annually
Current diagnostic pathways rely heavily on
- Static MRI interpretation
- Subjective clinical assessment
- Delayed referral processes
- Resource-intensive imaging infrastructure
Structure and function remain disconnected
Despite increasing use of imaging, there remains no widely accessible, objective system that integrates how the knee looks with how the knee moves.
MAI-KNEE™ addresses this gap.
About the Programme
What MAI-KNEE™ is designed to deliver
MAI-KNEE™ builds upon the clinically validated MAI Motion platform and extends it into a multi-modal diagnostic framework.
AI-driven 3D motion analysis
Combining markerless movement capture with the clinically validated MAI Motion platform.
Anatomical MRI insight
Integrating structural imaging alongside dynamic function rather than in isolation.
Interpretable digital biomarkers
Generating outputs designed to be read and acted on within clinical pathways.
Earlier stratification
Enabling earlier stratification of knee osteoarthritis and more personalised treatment pathways.
Rather than relying solely on structural imaging, MAI-KNEE™ is designed to interpret dynamic function alongside anatomy, creating a more complete clinical picture.
A regulated digital
medical device vision.
MAI-KNEE™ has been architected with the intention of regulatory progression as a Class II medical device application, designed for deployment via standard mobile devices.
This reflects a broader strategy of moving from episodic imaging to continuous, intelligence-driven care.
Accessible home-based assessment
Objective biomechanical quantification
Reduced reliance on repeated MRI scans
Earlier identification of patients requiring intervention
Strategic Importance
A significant step in a long-term ambition.
This programme represents a significant step in MSK Doctors’ long-term ambition to:
- Reduce diagnostic delay
- Improve stratification precision
- Support NHS efficiency
- Lower unnecessary imaging burden
- Integrate AI into routine musculoskeletal care
The proposal builds on prior Innovate UK collaborations and internal validation work conducted within our in-house motion capture and imaging facilities.
Commercial & Health System Alignment
Affordability with clinical depth.
MAI-KNEE™ is positioned within rapidly expanding digital healthcare and mobile health markets. Its intended model supports:
NHS integration
Subscription-based digital deployment
B2B healthcare partnerships
International scalability
Licensing with implant and robotic companies
By combining affordability with clinical depth, MAI-KNEE™ is designed to deliver both socio-economic and system-level benefit.
Current Status
Part of an active innovation roadmap.
MAI-KNEE™ remains part of MSK Doctors’ active innovation roadmap. Development work continues to refine:
01
Multimodal AI algorithms
02
Motion–MRI correlation modelling
03
Clinical biomarker validation
04
Regulatory preparation
05
Platform scalability
From Interpretation to Intelligence
This programme reflects a strategic commitment to bridging biomechanics and anatomy — advancing musculoskeletal care from interpretation to intelligence.
MAI-KNEE™ is a strategic AI-enabled diagnostic innovation developed by MSK Doctors and formally submitted through the Innovate UK Smart Grants programme, continuing to progress within our active innovation pipeline.
Academic & Clinical Collaboration
We are actively seeking strategic partners and academic consortiums to accelerate these programmes towards clinical reality.